The TARGET-D randomized clinical trial followed 630 adults (average age 63, 78% male) with acute coronary syndrome for an average of 4.2 years. Over 85% of participants began the study with vitamin D levels below 40 ng/mL. Participants were randomized into either a standard care group or a treatment group that received personalized vitamin D doses, which were adjusted every three months to achieve a target blood level of 40-80 ng/mL; notably, nearly 52% of this group required over 5,000 IU daily to reach this target. While this tailored approach did not significantly reduce the primary composite outcome of death, heart failure hospitalization, or stroke (MACE), it was associated with a 52% lower risk of heart attack. These preliminary findings require validation in a follow up cohort to eliminate the risk of data mining.

Personalized vitamin D3 dosing halved repeat heart attacks in an Intermountain trial
A shared summary describes an Intermountain Health trial of 630 recent heart attack survivors in which vitamin D3 was dosed individually to keep blood levels above 40 ng/mL. Repeat heart attacks were lower, though total major cardiovascular events were not, and larger trials are needed.
